Artificial Intelligence in Healthcare Guidelines (AIHGle 2.0)
Singapore · Guideline · Ministry of Health and Health Sciences Authority
Our summary
Singapore's guidance framework for the safe and responsible development, deployment, and use of artificial intelligence in healthcare settings. It clarifies roles and responsibilities for developers, deployers such as healthcare organisations, and users such as healthcare professionals. The guidelines emphasize augmenting healthcare delivery with AI while ensuring patient safety, clinical effectiveness, and transparency to build trust across the healthcare ecosystem.
Written by the Index in our own words. It is not legal advice; the official text is the authority.
Inside this policy
Every section of this policy in order. Our notes summarise each one in plain language and do not quote the official text, which is the authority.
Drafted by the Index An automated summary of the official text, not yet reviewed by a person.Reviewed Checked by a person against the official text.
8 sections
Jump to a chapter
Artificial Intelligence
AI is used across healthcare for administrative, clinical support and research functions. While it offers major benefits for patient outcomes, responsible design and use are essential to manage inherent risks.
AI in Healthcare Guidelines
Singapore's MOH and HSA have developed AIHGle 2.0, which guides safe and responsible development, deployment and use of AI by developers, deployers and healthcare professionals. The framework emphasises stakeholder accountability, transparency for informed decision-making, and risk assessment practices.
Download materials
Precision Medicine
Precision medicine uses genetic testing, biomarkers and AI algorithms for early disease detection and personalised treatment. MOH addresses challenges including complex result interpretation, scientific evidence gaps, consumer awareness, data privacy and genetic discrimination through regulation, guidance and a moratorium on genetic testing in insurance.
Regulation of Genetic Testing
MOH's Code of Practice sets minimum standards for clinical genetic and genomic testing by healthcare institutions and practitioners. The code is being converted into regulations under the Healthcare Services Act.
Non-clinical Genetic Testing
MOH provides guidance for direct-to-consumer genetic testing providers to ensure consumer safety, welfare and privacy. The guidance addresses risks including unreliable results and unauthorised use of genetic data.
Moratorium on the Use of Genetic Test Results in Insurance Underwriting
MOH and the Life Insurance Association prohibit licensed insurers and reinsurers from using genetic test results in underwriting decisions, enabling individuals to pursue genetic testing and precision medicine research without insurance discrimination concerns.
Download documents
Controls
What this policy requires, forbids, grants or penalises, one control at a time and in our own words. Each control links to the official text, which is the authority. This is not legal advice.
Drafted by the Index Drafted automatically from the official text, not yet reviewed by a person.Reviewed Checked by a person against the official text.
Themes covered 9 of 35
Choose a theme to see only its controls. About the themes
Risk and scope 2 of 4
- Risk classification, not covered
- Impact assessment, not covered
Data and privacy 2 of 4
- Cross-border data transfer, not covered
- Copyright and training data, not covered
Transparency and records 1 of 4
- Labelling of synthetic content, not covered
- Technical documentation, not covered
- Record keeping and logging, not covered
Technical safeguards 2 of 4
- Human oversight, not covered
- Testing and evaluation, not covered
Assurance and lifecycle 0 of 4
- Conformity assessment and certification, not covered
- Registration and notification, not covered
- Incident and breach reporting, not covered
- Post-market monitoring and corrective action, not covered
Rights and protected groups 0 of 4
- Automated decision-making rights, not covered
- Children and vulnerable groups, not covered
- Biometric identification and surveillance, not covered
- Whistleblowing, complaints and redress, not covered
Roles and organisation 1 of 6
- Supply chain and provider-deployer duties, not covered
- General purpose and foundation models, not covered
- Training and AI literacy, not covered
- Public sector use and procurement, not covered
- Innovation support and sandboxes, not covered
Enforcement and sectors 1 of 5
- Enforcement, penalties and regulators, not covered
- Sector rules: finance and insurance, not covered
- Sector rules: employment, not covered
- Sector rules: education, not covered
The full list of controls could not be loaded, so only the first 10 are shown.
AI in Healthcare Guidelines 4 controls
- ObligationApplies to: Public authorityDrafted by the Index
The MOH and HSA should develop and update guidance to enable healthcare organisations and professionals to use AI safely and responsibly.
- ObligationApplies to: AnyoneDrafted by the Index
Developers, deployers and healthcare professionals should understand and accept accountability for their respective roles in implementing AI systems.
- Applies to: DeployerDrafted by the Index
Deployers and users should receive guidance on transparency practices that enable informed decision-making about AI use in healthcare.
- ObligationApplies to: DeployerDrafted by the Index
Healthcare organisations should assess and mitigate risks before and during deployment of AI systems.
Precision Medicine 2 controls
- ObligationApplies to: Public authorityDrafted by the Index
The MOH should regulate the provision of genetic testing and genomic testing services by healthcare practitioners and institutions.
- ProhibitionApplies to: OthersDrafted by the Index
Insurers must not use genetic testing results as a basis for underwriting decisions.
Regulation of Genetic Testing 1 control
- ObligationApplies to: ProviderDrafted by the Index
Healthcare institutions and practitioners must comply with minimum standards and requirements for genetic and genomic testing set out in the MOH Code of Practice.
Non-clinical Genetic Testing 2 controls
- ObligationApplies to: ProviderDrafted by the Index
Providers of non-clinical or direct-to-consumer genetic testing should ensure safety, welfare and privacy of consumers.
- ProhibitionApplies to: ProviderDrafted by the Index
Providers of non-clinical or direct-to-consumer genetic testing should prevent unauthorised commercialisation of genetic data obtained from tests.
Moratorium on the Use of Genetic Test Results in Insurance Underwriting 1 control
- ProhibitionApplies to: OthersDrafted by the Index
Licensed life insurers and reinsurers that are members of the Life Insurance Association must not use genetic test results in insurance underwriting decisions.
Change history
No changes recorded since we began monitoring this policy.